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Summary Fifteen published randomised trials comparing adjuvant chemotherapy with no chemotherapy in
soft-tissue sarcoma (STS) were identified (1546 patients). A qualitative review and a meta-analysis of this
published literature were performed. With the qualitative review it was not possible to synthesise the
apparently conflicting results of individual trials. The meta-analysis of the published data suggests an
improvement in survival at 2 years (OR = 0.73, 95% CI = 0.53-0.99, P = 0.044) and at 5 years (OR = 0.59,
95% CI = 0.45-0.78, P = 0.0002) in favour of chemotherapy. However, the assumptions and approximations
required to conduct this quantitative summary demand that the results are interpreted with caution. The only
reliable means of assessing the current evidence on whether adjuvant chemotherapy has a role in the treatment
of patients with STS, is to collect, check and reanalyse individual patients data (IPD) from each trial centrally,
and formally combine the results in a stratified time-to-event analysis. Such an IPD analysis is currently being
undertaken by an international collaborative group.
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Soft-tissue sarcomas (STS) are tumours of mesenchymal
origin arising throughout the body which in total account for
only 1% of all malignancies (Pinedo and Verweij, 1986).
Approximately 90% of all STS patients present with appar-
ently localised masses and no clinical evidence of metastasis
(Rosenberg et al., 1983). Where anatomically possible, initial
treatment usually involves radical surgery (Souhami, 1986),
although good control of the primary tumour can also be
achieved by conservative surgery in conjunction with
radiotherapy (Mazanet and Antman, 1991). Despite good
local control, around 50% of patients with high-grade
tumours will die from metastatic disease (Delaney et al.,
1991). Thus, there has been interest in the potential of
adjuvant chemotherapy to control micrometastases and imp-
rove survival.
A number of randomised clinical trials have compared
local surgical treatment (with or without radiotherapy) fol-
lowed by adjuvant chemotherapy with local treatment alone.
As in many other areas of cancer research, these trials have
not been large enough to demonstrate moderate treatment
effects with reliability. Almost all have involved fewer than
250 patients, although one trial conducted by the European
Organization for Research and Treatment into Cancer has
recruited 468 patients (Bramwell et al., 1994). Thus, these
trials are unlikely to produce conventionally significant
results, and could easily be interpreted as 'negative trials'. A
more appropriate interpretation would be to consider them
as being inconclusive trials.
Although individual trials may have insufficient numbers
of patients to detect moderate survival benefits, 'combining'
the results of these trials might indicate whether adjuvant
chemotherapy is likely to be beneficial in the treatment of
STS. This paper therefore reviews qualitatively, then quan-
titatively, the results of all published randomised trials of
adjuvant chemotherapy in STS.
Materials and methods
Published randomised trials of chemotherapy in STS were
identified using the Medline and Cancerlit databases and by
examining the reference lists of already identified trials,
review articles and books.
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Trials that randomised adult patients with localised, resec-
table STS to receive either adjuvant chemotherapy or no
chemotherapy following local treatment were eligible for inc-
lusion in the meta-analysis, provided that the treatment com-
parison was unconfounded. Also, trials were required to have
used a randomisation method which precluded prior
knowledge of treatment assignment and to have taken place
between 1 January 1970 and 31 December 1992.
Of 20 potentially eligible trials, four were excluded because
they were non-adjuvant trials that randomised patients with
advanced disease only (Schoenfeld et al., 1982; Pinedo et al.,
1984; Baker et al., 1987; Borden et al., 1990) and one because
all patients received induction chemotherapy before ran-
domisation (Eilber et al., 1988). Relevant details and results
were extracted from most recent publications of the 15
remaining trials and collated to form the basis of the
qualitative review and meta-analysis.
For the meta-analysis, 2 year and 5 year survival rates
were taken from the most recent publication for each trial
(except in one instance where they were taken from an earlier
publication) and analysed using the methods described below
(Stewart, 1992). If the 2 year and 5 year survival figures were
not quoted, they were estimated from the published survival
curves and the numbers at risk reduced, where appropriate,
to allow for immature follow-up (Stewart and Parmar, 1993).
This technique, which assumes proportional hazards, stan-
dardises the relative results of trials with differing lengths of
follow-up. Additionally, the survival rates at maximum
follow-up were extracted from those publications that
reported it. For each trial, the odds ratio (OR) was cal-
culated from the number of patients at risk and the observed
number of deaths on each arm.
OR = exp[(Ot-Et/VJ
where Ot is the observed number of deaths in the treatment
arm, Et is the expected number of deaths in the treatment
arm under the hypothesis of no difference and V is the
variance and Nt(Ot +0c)
N
V=Et(l-NtIN)(N-Ot - 0
N-I
where 0c is the observed number of deaths on control, Nt is
the total number ofpatients randomised to receive treatment
and N is the total number of patients randomised.Adjuvantchemotherapy forsoft-tissue sarcoma
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Confidence intervals for each odds ratio were calculated
using the expression exp [(O°-E,)/V± T/IVV, where y takes
the values 1.96 and 2.58 for the 95% and 99% intervals
respectively. The overall odds ratio, combined across all
trials, was calculated as follows (Early Breast Cancer
Trialists' Collaborative Group, 1990):
Overall OR=exp [(Z(04-E))/1VI
where the summation is across all trials. The overall 95%
confidence intervals were calculated as exp [Z(Ot-Et)/11V+
1.96/V-I V.
In the main text of this paper and in Table I, the total
number of patients randomised are presented. However, the
calculated odds ratios are based on fewer patients, because
some trials report on a defined subset of patients only or
exclude patients from their analysis. Furthermore, as men-
tioned above, the number of patients at risk are adjusted to
allow for censoring.
Results
Fifteen eligible randomised trials comparing adjuvant
chemotherapy with no adjuvant chemotherapy in localised
STS were identified. These trials, initiated between 1973 and
1983, recruited a total of 1546 patients. Summaries of each
trial, including the drug regimens used, sites treated, grades
of disease and number of patients randomised, are given in
Table I.
Chemotherapy regimen
All 15 trials used doxorubicin either as a single agent (seven
trials, 770 patients) or in combination (eight trials, 776
patients) probably because it has been observed to be one of
the most active single agents in advanced disease (Pinedo and
Verweij, 1986). Those trials which used combination
chemotherapy included doxorubicin and cyclophosphamide
plus one or more of vincristine, methotrexate, dactinomycin
and dacarbazine. The total dose of doxorubicin, whether
given as a single agent or in combination, varied between 360
and 550 mg m-2, except in one instance where the dose was
200 mg m-2 (Edmonson et al., 1985). In two trials (Antman
et al., 1984; Picci et al., 1988), a subset of patients in both
arms received induction chemotherapy before being ran-
domised to adjuvant chemotherapy, accounting for 14 and 29
patients respectively.
Surgery
In all trials, patients underwent either radical or conservative
surgery. If the latter, local resection was generally followed
by radiotherapy. In those studies reporting it, the delay
between primary treatment and the start of chemotherapy
was between 1 week and 4 months.
Tumour site
Most trials included a variety of primary sites with two trials
(Chang et al., 1988; Picci et al., 1988; 269 patients) restricted
to extremities alone. The most recent reports of a further two
trials presented survival information only for extremity
patients (Benjamin et al., 1987; Baker, 1988). Across all
trials, the extremities were the main tumour sites accounting
for more than half of all patients randomised. The remaining
tumour sites were head and neck, breast, trunk, ret-
roperitoneum and uterus, other sarcoma sites rarely being
included.
Status ofthe disease
Patients with metastatic disease were ineligible for inclusion
in all trials except one (Edmonson et al., 1984), although, in
another, metastases were found in some patients after ran-
domisation (AlvegArd et al., 1989). However, many trials
included both patients with primary and locally recurrent
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disease (Antman et al., 1984; Edmonson et al., 1985; Ben-
jamin et al., 1987; Bramwell et al., 1988; Chang et al.,
1988).
Histological grade
Histological grade was not reported for the uterine trials
(Omura et al., 1985; Piver et al., 1988). Two trials included
patients with all histological grades (Edmonson et al., 1985;
Lerner et al., 1987) and one entered patients with all but very
low-grade sarcomas (Bramwell et al., 1994). Most of the
remaining trials concentrated on patients with intermediate
and high-grade sarcomas (Antman et al., 1984; Glenn et al.,
1985a,b; Benjamin et al., 1987; Baker, 1988; Chang et al.,
1988; Kinsella et al., 1988; Ravaud et al., 1990) or high-grade
sarcomas only (Picci et al., 1988; Alvegard et al., 1989).
Endpoints
All trials reported principally on the end points of survival
and disease-free survival, although some also reported on
local and distant recurrence.
Results ofindividual trials
Table I gives the reported 2 and 5 year survival for each
individual trial. It can be seen from this table, which also
provides a brief summary of the conclusions of individual
trials, that a number of different, and apparently contradic-
tory, conclusions have been reached.
Qualititative summary ofresults
Fifteen randomised trials assessed doxorubicin-based
adjuvant chemotherapy, following surgery, in localised, resec-
table STS. Two trials reported a significant reduction in local
recurrence with adjuvant chemotherapy (Chang et al., 1988;
Ravaud et al., 1990) and one trial reported a significant
improvement in metastasis-free survival (Ravaud et al.,
1990). Altogether, 5 of the 15 trials reported some form of
significant improvement in the disease-free survival at the
conventional level (0.05), four using combination
chemotherapy (Benjamin et al., 1987; Chang et al., 1988;
Ravaud et al., 1990; Bramwell et al., 1994) and one using
single-agent doxorubicin (Picci et al., 1988). However, only
two trials reported conventionally significant improvements
in overall survival (Picci et al., 1988; Ravaud et al.,
1990).
From a qualitative review of this published information, it
is therefore very difficult to assess whether adjuvant
chemotherapy does or does not have a role in the treatment
of STS.
Quantitative summary ofthe results
The disease-free survival rates were not combined to produce
an overall OR, because this is a more subjective and
therefore a less reliable end point from overall survival. More
importantly perhaps, as complete definitions of disease-free
survival were not given in most of the trial reports, it is
difficult to assess the practical importance of this end point
with the available data.
Figure 1 displays the ORs and their confidence intervals
for 2 year survival, calculated for each of the 13 trials with
available data. Two trials are not shown on this figure. The
first (Kinsella et al., 1988) because it did not report the
results of the eight patients randomised and the second (Ben-
jamin et al., 1987) because it did not provide estimates of 2
year survival.
Few deaths had occurred at 2 years, and for most trials the
confidence intervals are wide and cross the equivalence line.
The estimated odds ratios for individual trials lie on both
sides of this line. This variability is further reflected in the
test for heterogeneity (X2 = 23.75, d.f. = 12, P = 0.022), which
may in part be explained by the extreme OR estimate and
narrow confidence intervals of the Bergonie trial (Ravaud et
al., 1990). However, it is difficult to pinpoint sources of
heterogeneity with this type of data.
Combining the results of the individual trials gives an
overall odds ratio of 0.73 [95% confidence interval
Odds
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0 * 1.03 (0.39-2.71)
* 0.43 (0.02-7.54)
* 0.41 (0.05-3.47)
* 0.21 (0.02-2.10)
* 0.81 (0.31-2.12)
0.29 (0.05-1.48)
* 0.59 (0.08-4.42)
* 0.36 (0.03-5.10)
* 0.73 (0.10-5.13)
2.31 (0.25-21.09)
10.87 (0.59-1.04)
0 1.03 (0.03-2.22)
0.11 (0.02-0.58)
0.73 (0.53-0.99)
0.0 0.5 1.0 1.5 2.0
Chemo better No chemo better
Figure 1 Meta-analysis, at 2 years, of published randomised trials of adjuvant chemotherapy for soft-tissue sarcoma. The odds
ratio (OR) for each trial is represented by the centre square on each bar, the size of which is directly proportional to the amount of
information available in the trial. The inner and outer limits of the bar indicate the 95% and 99% confidence intervals respectively.
The line drawn through the OR value of 1.0 indicates no difference between the two treatment arms. An OR to the left of this
equivalence line suggests an advantage for chemotherapy, whereas an OR lying to the right suggests an advantage for no
chemotherapy. If a confidence interval crosses this line then the results for that trial did not reach significance at the 0.01 level.
Finally, the black diamond at the base of the plot gives the overall odds ratio (across all trials) and the extremes of the diamond
give the 95% confidence interval.
No. events/no. entered
Chemo Nochemo O-E Variance Reference
GOG
Roswell
DF/MGH
ECOG
SSG
Rizzoli
IGSC
Mayo
NCI 1
NCI 2
NCI 3
EORTC
Bergonie
18l75
1/8
2/17
2/13
17/87
2/31
5/17
1/30
4/37
5/16
4/8
25/145
1/30
19/81
3/11
5/19
2/13
19/82
10/42
5/12
3/31
4/28
2/13
0/7
29/172
11/27
0.21
-0.68
-1.31
-1.96
-1.53
-3.10
-0.86
-0.97
-0.55
1.14
1.87
0.30
-5.32
7.09
0.81
1.45
1.25
7.12
2.48
1.65
0.95
1.75
1.36
0.78
11.15
2.40
Total 87/514 115/535 -12.8 40.25(CI) = 0.53-0.99] in favour of chemotherapy (P = 0.044).
This suggests that the use of adjuvant chemotherapy gives a
27% reduction in the risk of death at 2 years (95%
CI= 1-47%), which translates into an absolute benefit of
5% (95% CI = 0.2-9%), improving survival from 76% to
81%. However, it is probably clinically inappropriate to
focus only on a result based on this relatively short period of
follow-up.
The results of the analysis at 5 years are given in Figure 2.
Estimates of 5 year survival were not available for four trials
(Antman et al., 1984; Glenn et al., 1985b; Baker et al., 1988;
Kinsella et al., 1988). At this stage, all the ORs for the
individual trials lie to the left of the equivalence line and the
CIs are generally narrower, reflecting the increased number
of deaths recorded by this time point. There is no gross
statistical heterogeneity across trials (X2= 10.54, d.f. = 10,
P = 0.394). The overall 5 year OR of 0.59 (95%
CI = 0.45-0.78) is a more reliable estimate of the treatment
effect and is again in favour of chemotherapy (P = 0.0002).
This suggests a 41% reduction in the risk of death (95%
CI = 22-55%) at 5 years. This corresponds to a 12% (95%
CI = 6-17%) improvement in absolute survival at 5 years,
increasing survival from 57% to 69%.
The OR calculated using the total number of observed
deaths in the ten trials that reported it (Antman et al., 1984;
Glenn et al., 1985a,b; Omura et al., 1985; Lerner et al., 1987;
Baker et al., 1988; Picci et al., 1988; Piver et al., 1988;
Ravaud et al., 1990; Bramwell et al., 1994) is 0.61 (95%
CI = 0.46-0.82, P = 0.003), which is very similar to that
calculated at 5 years. This analysis suggests that the overall
odds of dying are reduced by 39% (95% CI = 18-54%) for
those patients who are treated with chemotherapy.
Although the results at 2 and 5 years and using the total
number of deaths are promising, they should be interpreted
with caution because the analyses are subject to a number of
possible biases and problems, which are discussed below.
Discussion
This paper aimed to assess the role of adjuvant
chemotherapy in soft-tissue sarcoma, by reviewing all pub-
lished trials which have randomised patients to receive
adjuvant chemotherapy or no adjuvant chemotherapy follow-
ing surgery (± radiotherapy). Unfortunately, it has not been
possible through either a qualitative or quantitative review of
the literature to resolve this issue completely satisfactorily.
The qualitative review suffers from the difficulties inherent
in trying to review a number of apparently equivocal or
Adjuvantchemotherapyforsoft-tissue sarcoma
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conflicting trials and no firm conclusions can be drawn.
Previous reviews of the literature (Delaney et al., 1991;
Mazanet and Antman, 1991; Elias, 1993; Mertens and
Bramwell, 1993; Zalupski, 1993a) have been similarly inconc-
lusive.
Despite being more objective and authoritative and pro-
ducing an encouraging result, the meta-analysis based on
data extracted from the literature suffers from a number of
possible biases. For example, publication bias, inappropriate
patient exclusions, variable follow-up times and a fixed time
point analysis can all lead to an overestimate of the size of
the treatment effect and its significance compared with that
obtained with the individual patient data (Stewart and Par-
mar, 1993). Furthermore, the principal analyses we have been
able to perform were based on estimated 2 year and 5 year
survival figures. Such analyses take no account of the relative
pattern of survival before 2 years, between 2 and 5 years and
after the 5 year time point and, thus, give little indication of
the overall survival experience on the two treatments. A more
detailed analysis over many different time periods was not
possible, as the information required could not be adequately
extracted from the trial publications.
Using the overall numbers of deaths in each trial to cal-
culate an OR can also be problematic and was the method
used in another meta-analysis of the published results (Jones
et al., 1991). Not all trial publications report the overall
number of deaths, and the length of follow-up varies con-
siderably among those that do. Therefore, the calculated OR
for each trial is based on a different point in time. This may
be appropriate if death ratios remain constant over time (the
hazards are proportional), but not, for example, if survival
curves converge or even diverge after some years. As this
may well be the case with chemotherapy in STS, it is not
altogether clear how to interpret this type of analysis.
Another similar meta-analysis of the published literature
(Zalupski et al., 1993b) used an alternative method (logistic
regression) to combine overall survival rates, but concen-
trated on trials including STS of the extremities. Again there
was a strong indication of treatment benefit in terms of
survival. However, despite trying to control for the estimated
sample size and length of follow-up in each trial, other
potential sources of bias such as publication bias, patient
exclusions, censoring and the use of single time point
estimates of survival still exist. Therefore, this result must
also be regarded with caution.
Our experience in undertaking this meta-analysis based on
published data reflects that of other workers carrying out
similar projects in different disease sites. They concluded that
it was not possible to perform meta-analyses of the literature
No. events/no. entered
Chemo Nochemo O-E Variance
29/67
3/8
3/7
21/60
3/23
5/20
3/26
7/39
4/12
46/145
4/26
39/72
7/11
3/6
22/57
10/30
9/23
7/27
11/28
4/10
64/172
14/23
-3.78
-1.21
-0.23
-1.05
-2.64
-1.51
-1.91
-3.48
-0.36
-4.32
-5.55
8.74
1.22
0.87
6.85
2.46
2.40
2.07
3.25
1.32
17.88
2.90
Total 128/433 190/459 -26.0 49.96
Odds ratio
0.65 (0.27-1.55)
I' D * 0.37 (0.04-3.83)
I' * 0.77 (0.05-12.20)
0.86 (0.32-2.30)
*' I 0.34 (0.07-1.77)
I t3 * 0.53 (0.10-2.82)
* 0.40 (0.07-2.39)
IIt- 0.34 (0.08-1.44)
I I * 0.76 (0.08-7.16)
0.79 (0.43-1.45)
I' iI 0.15 (0.03-0.67)
*_ 0.59 (0.45-0.78)
0.0 0.5 1.0 1.5 2.0
Chemo better No chemo better
Figure 2 Meta-analysis, at 5 years, of published randomised trials of adjuvant chemotherapy for soft-tissue sarcoma.
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to address specific questions in lung (Nicolucci et al., 1989)
and ovarian (Marsoni et al., 1990) cancer because of the
poor quality of data retrieved from the publications and the
subsequent assumptions required to perform the analyses.
In addition, this type of meta-analysis based on published
data does not allow the investigation of whether any
observed effect is consistent across different subgroups, for
example disease sites or histological types. Similarly, the issue
of whether polychemotherapy and single-agent chemotherapy
are equally effective could not be examined. These additional
questions can only be investigated in a meta-analysis of
individual patient data. Likewise, by collecting data for each
patient, those subsets of patients that received neoadjuvant
chemotherapy (Antman et al., 1984; Picci et al., 1988) could
be excluded from the analysis.
There may be sufficient evidence from completed ran-
domised trials to assess whether chemotherapy does or does
not improve the survival of patients with STS. Unfor-
tunately, it has not been possible to synthesise satisfactorily
the results of individual trials on the basis of the information
given in the literature in either a qualitative or a quantitative
manner. The more objective, but nevertheless flawed, meta-
analysis of the published data does provide evidence to sug-
gest that chemotherapy may improve the survival of patients
with this disease. However, the only reliable means of
confirming this preliminary result is to collect individual data
on all patients randomised, in all eligible trials and to com-
bine the results of these trials through an appropriate time-
to-event analysis, stratified by trial. We have therefore
initiated an international collaborative meta-analysis to col-
lect these data. Both unpublished and published trials will be
sought by electronic database searching, hand searching of
relevant journals, review article bibliographies, meeting
abstracts and trial registers and by contacting experts in the
field. Furthermore, using time-to-event data from all patients
randomised in intention-to-treat analyses will allow us to
explore whether any effect of adjuvant chemotherapy is con-
sistent across disease sites, histological types and grades of
disease and with tumour size and the extent of resection.
References
ALVEGARD TA, SIGURDSSON H, MOURIDSEN H, SOLHEIM 0,
UNSGAARD B, RINGBORG U, DAHL 0, NORDENTOFT A, BLOM-
QVIST C, RYDHOLM A, STENER B AND RANSTAM J. (1989).
Adjuvant chemotherapy with doxorubicin in high grade soft tis-
sue sarcoma: a randomized trial of the Scandinavian Sarcoma
Group. J. Clin. Oncol., 7, 1504-1513.
ANTMAN K, SUIT H, AMATO D, CORSON J, WOOD W, PROPPE K,
HARMON D, CAREY R, GREENBERG J, BLUM R AND WILSON
R. (1984). Preliminary results of a randomized trial of adjuvant
doxorubicin for sarcomas: lack of apparent difference between
treatment groups. J. Clin. Oncol., 2, 601-608.
BAKER LH, FRANK J, FINE G, BALCERZAK SP, STEPHENS RL,
STUCKEY WJ, RIVKIN S, SAIKI J AND WARD JH. (1987). Com-
bination chemotherapy using adriamycin, DTIC, cyclophos-
phamide, and actinomycin D for advanced soft tissue sarcomas: a
randomized comparative trial. A phase III Southwest Oncology
Group study (7631). J. Clin. Oncol., 5, 851-861.
BAKER LH. (1988). Adjuvant therapy for soft tissue sarcomas. In
Recent Concepts in Sarcoma Treatment, Ryan JR and Baker LH
(eds) pp. 130-135. Kluwer Academic Publishers: Dordrecht.
BENJAMIN RS, TERJANIAN TO, FENOGLIO CJ, BARKLEY HT,
EVANS HL, MURPHY WK AND MARTIN RG. (1987). The impor-
tance of combination chemotherapy for adjuvant treatment of
high-risk patients with soft-tissue sarcomas of the extremities. In
Adjuvant Therapy of Cancer, Vol. V, Salmon SE (ed.)
pp. 735-744. Grune & Stratton: Orlando.
BORDEN EC, AMATO DA, EDMONSON JH, RITCH PS AND
MASANORI S. (1990). Randomized comparison of doxorubicin
and vindesine to doxorubicin for patients with metastatic soft-
tissue sarcomas. Cancer, 66, 862-867.
BRAMWELL V, ROUESSE J, STEWARD W, SANTORO A,
SCHRAFFORDT-KOOPS H, BUESA J, RUKA W, PRIARIO J,
WAGENER T, BURGERS M, VAN UNNIK J, CONTESSO G,
THOMAS D, VAN GLABBEKKE M, MARKHAM D AND PINEDO
H. (1994). Adjuvant CYVADIC chemotherapy for adult soft
tissue sarcoma - reduced local recurrence but no improvement in
survival: a study of the European Organization for Research and
Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J.
Clin. Oncol., 12, 1137-1149.
CHANG AE, KINSELLA T, GLATSTEIN E, BAKER AR, SINDELAR
WF, LOTZE MT, DANFORTH DN, SUGARBAKER P, LACK E,
STEINBERG SM, WHITE DE AND ROSENBERG SA. (1988).
Adjuvant chemotherapy for patients with high-grade soft-tissue
sarcomas of the extremity. J. Clin. Oncol., 6, 1491-1500.
DELANEY TF, YANG JC AND GLATSTEIN E. (1991). Adjuvant
therapy for adult patients with soft tissue sarcomas. Oncology, 5,
105-118.
EARLY BREAST CANCER TRIALISTS' COLLABORATIVE GROUP.
(1990). Treatment of Early Breast Cancer, Vol I. Worldwide
Evidence 1990. Oxford University Press: Oxford.
EDMONSON JH. (1985). Systemic chemotherapy following complete
excision of nonosseous sarcomas: Mayo Clinic experience. Cancer
Treat. Symp., 3, 89-97.
EDMONSON JH, FLEMING TR, IVINS JC, BURGERT EO, SOULE EH,
O'CONNELL MJ, SIM FH AND AHMANN DL. (1984). Ran-
domized study of systemic chemotherapy following complete
excision of nonosseous sarcomas. J. Clin. Oncol., 2,
1390-1396.
EILBER FR, GIULIANO AE, HUTH JF AND MORTON DL. (1988). A
randomized prospective trial using postoperative adjuvant
chemotherapy (Adriamycin) in high-grade extremity soft tissue
sarcoma. Am. J. Clin. Oncol., 11, 39-45.
ELIAS AJ. (1993). Chemotherapy for soft-tissue sarcomas. Clin.
Orthopaed. Rel. Res., 289, 94-105.
GLENN J, KINSELLA T, GLATSTEIN E, TEPPER J, BAKER A,
SUGARBAKER P, SINDELAR W, ROTH J, BRENNAN M, COSTA J,
SEIPP C, WESLEY R, YOUNG RC AND ROSENBERG SA. (1985a).
A randomized, prospective trial of adjuvant chemotherapy in
adults with soft tissue sarcomas of the head and neck, breast, and
trunk. Cancer, 55, 1206-1214.
GLENN J, SINDELAR W, KINSELLA T, GLATSTEIN E, TEPPER J,
COSTA J, BAKER A, SUGARBAKER P, BRENNAN M, SEIPP C,
WESLEY R, YOUNG R AND ROSENBERG SA. (1985b). Results of
multimodality therapy of resectable soft-tissue sarcomas of the
retroperitoneum. Surgery, 97, 316-325.
JONES GW, CHOUINARD E AND PATEL M. (1991). Adjuvant
Adriamycin (doxorubicin) in adult patients with soft-tissue sar-
comas: a systematic overview and quantitative meta-analysis.
Clin. Invest. Med., 14 (Suppl. 19), A772.
KINSELLA T, SINDELAR W, LACK E, GLATSTEIN E AND
ROSENBERG SA. (1988). Preliminary results of a randomized
study of adjuvant radiation therapy in resectable adult ret-
roperitoneal soft tissue sarcomas. J. Clin. Oncol., 6, 18-25.
LERNER HJ, AMATO DA, SAVLOV E, DEWYS WD, MITTELMAN A,
URTASUN RC, SOBEL S AND SHIRAKI M. (1987). Eastern
Cooperative Oncology Group: a comparison of adjuvant dox-
orubicin and observation for patients with localized soft tissue
sarcoma. J. Clin. Oncol., 5, 613-617.
MAZANET R AND ANTMAN KH. (1991). Adjuvant therapy for sar-
comas. Semin. Oncol., 18, 603-612.
MARSONI S, TORRI V, TAIANA A, GAMBINO A, GRILLI R, LIATI P,
FRANZOSI MG, PISTOTTI V, FOCARILE F AND LIBERATI A.
(1990). Critical review of quality and development of randomised
clinical trials (RCTs) and their influence on the treatment of
advanced epithelial ovarian cancer. Ann. Oncol., 1, 343-350.
MERTENS WC AND BRAMWELL VHC. (1993). Adjuvant
chemotherapy in the treatment of soft-tissue sarcoma. Clin.
Orthopaed. Rel. Res., 289, 81-93.
NICOLUCCI A, GRILLI R, ALEXANIAN A, APOLONE G, TORRI V
AND LIBERATI A. (1989). Quality evaluation and clinical implica-
tions of randomised controlled clinical trials on the treatment of
lung cancer: lost opportunity for meta-analysis. JAMA, 262,
2101-2107.Adjuvant chemotherapy forsoft-issue sarcoma
JF Tierney etal
475
OMURA A, BLESSING JA, MAJOR F, LIFSHITZ S, EHRLICH CE,
MANGAN C, BEECHAM J, PARK R AND SILVERBERG S. (1985).
A randomised trial ofadjuvant adriamycin in uterine sarcomas: a
Gynecologic Oncology Group study. J. Clin. Oncol., 3,
1240-1245.
PICCI P, BACCI G, GHERLINZONI F, CAPANNA R, MERCURI M,
RUGGIERI P, BALDINI N, AVELLA M, PIGNATTI G AND MANF-
RINI M. (1988). Results of randomized trial for the treatment of
localized soft tissue tumors (STS) of the extremities in adult
patients. In Recent Concepts in Sarcoma Treatment, Ryan JR and
Baker LH (eds) pp. 144-148. Kluwer Academic Publishers: Dor-
drecht.
PINEDO HM, BRAMWELL VHC, MOURIDSEN HT, SOMERS R, VEN-
DRIK CPJ, SANTORO A, BUESA J, WAGENER TH, VAN
OOSTEROM AT, VAN UNNIK JAM, SYLVESTER R, DE PAUW M,
THOMAS D AND BONADONNA G. (1984). Cyvadic in advanced
soft tissue sarcoma: a randomized study comparing two
schedules. Cancer, 53, 1825-1832.
PINEDO HM AND VERWEIJ J. (1986). The treatment of soft tissue
sarcomas with focus on chemotherapy: a review. Radiother.
Oncol., 5, 193-205.
PIVER MS, SHASHIKANT BL, MARCHETrI DL AND EMRICH LJ.
(1988). Effect of adjuvant chemotherapy on time to recurrence
and survival of stage I uterine sarcomas. J. Surg. Oncol., 38,
233-239.
RAVAUD A, BUI NB, COINDRE JM, KANTOR G, STOCKLE E,
LAGARDE Y, BECOUARN Y, CHAUVERGNE J, BONICHON F
AND MAREE D. (1990). Adjuvant chemotherapy with Cyvadic in
high risk soft tissue sarcoma: a randomized prospective trial. In
Adjuvant Therapy of Cancer, Vol. VI, Salmon SE (ed.)
pp. 556-566. WB Saunders: Philadelphia.
ROSENBERG SA, TEPPER J, GLATSTEIN E, COSTA J, YOUNG R,
BAKER A, BRENNAN MF, DEMOSS EV, SEIPP C, SINDELAR WF,
SUGARBACKER P AND WESLEY R. (1983). Prospective ran-
domized evaluation of adjuvant chemotherapy in adults with soft
tissue sarcomas of the extremities. Cancer, 52, 424-434.
ROSENBERG SA, CHANG AE AND GLATSTEIN E. (1985). Adjuvant
chemotherapy for treatment of extremity soft tissue sarcomas:
review of National Cancer Institute experience. Cancer Treat.
Symp., 3, 83-88.
SCHOENFELD DA, ROSENBAUM C, HORTON J, WOLTER JM, FALK-
SON G AND DECONTI RC. (1982). A comparison of adriamycin
versus vincristine and adriamycin, and cyclophosphamide versus
vincristine, actinomycin-D, and cyclophosphamide for advanced
sarcoma. Cancer, 50, 2757-2762.
SOUHAMI R AND TOBIAS J. (1986). Bone and soft tissue sarcoma.
In Cancer and its Management, pp. 389-405. Blackwell Scientific
Publications: Oxford.
STEWART LA. (1992). The role of overviews. In Introducing New
Treatments for Cancer: Practical, Ethical and Legal problems,
Williams CJ (ed.) pp. 384-401. John Wiley: Chichester.
STEWART LA AND PARMAR MKB. (1993). Meta-analysis of the
literature or of individual patient data: is there a difference?
Lancet, 341, 418-422.
ZALUPSKI MM, RYAN JR, HUSSEIN ME AND BAKER LH. (1993a).
Systemic adjuvant chemotherapy for soft tissue sarcomas of the
extremities. Surg. Oncol. Clins. N. Am., 2, 621-637.
ZALUPSKI MM, RYAN JR, HUSSEIN ME AND BAKER LH. (1993b).
Defining the role ofadjuvant chemotherapy for patients with soft
tissue sarcoma of the extremities. In Adjuvant Therapy ofCancer,
Vol. VII, Salmon SE (ed.) pp. 385-392. Lippincott: Philadel-
phia.